<DOC>
	<DOC>NCT02450461</DOC>
	<brief_summary>The purpose of this study is to answer the question whether a disease-specific profile of breath in patients with asthma can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.</brief_summary>
	<brief_title>Breath Analysis in Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1. Confirmed asthma. Diagnosis of asthma is made with episodic chest symptoms and a documented reversibility of at least 12% and/or 200 ml in FEV1 after 200 ug of inhaled salbutamol or airway hyperresponsiveness in the case of normal lung function testing (PC20 methacholine &lt; 4mg/ml) at the time of diagnosis. 2. Age between 18 and 80 years at study entry. 3. Healthy controls: neversmokers, normal spirometry (baseline FEV1 &gt; 85% predicted and FEV1/FVC greater than 0.7). 1. Asthma exacerbation within the last 6 weeks, defined as worsening of asthma symptoms requiring a change in therapy by a physician or a change in regular asthma therapy (including short course of oral corticosteroids) 2. Any lung disease other than asthma. 3. Acute inflammatory disease (e.g. common cold) within the last 4 weeks. 4. Regular intake of oral steroids. 5. Active smoking habits / positive history of smoking. 6. Acute or chronic hepatic disease. 7. Renal failure or renal replacement therapy. 8. Pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>